Literature DB >> 10911911

The epigenetics of colorectal cancer.

J P Issa1.   

Abstract

Colorectal cancer has provided an excellent model for studying the genetic basis of cancer and is one of the better-understood malignancies in this regard. The orderly progression of the disease, with distinct genetic alterations at each step, is a useful framework for deciphering the molecular basis of neoplasia. Epigenetics, the study of clonal changes in gene expression without associated genetic lesions, has raised increased interest recently, in part because of the identification of DNA methylation as a potential molecular mediator of the process. Several tumor-suppressor genes are silenced in various neoplasms in association with aberrant promoter methylation, and in the absence of coding region mutations. The study of DNA methylation changes in colorectal cancer has now provided additional clues into the pathogenesis of the disease. This review presents evidence for a model whereby DNA methylation changes play two distinct roles in the molecular evolution of colorectal cancer. Initially, progressive methylation and silencing of a subset of genes takes place in normal tissues as a function of age or time-dependent events and predisposes these normal cells to neoplastic transformation. At a later stage of disease progression, DNA methylation plays an important role in a subset of tumors affected by the CpG island methylator phenotype (CIMP), a recently identified pathway that results in a form of epigenetic instability through the simultaneous silencing of multiple genes. DNA methylation changes have important interactions with genetic lesions in this cancer type. CIMP+ cancers include the majority of tumors with sporadic mismatch repair deficiency through hypermethylation of the hMLH1 promoter, and also account for the majority of tumors with Ki-ras mutations through an unknown mechanism. By contrast, CIMP- cases evolve along a more classic genetic instability pathway, with a high rate of p53 mutations and chromosomal changes. Thus, the integration of epigenetic and genetic information provides a more complete molecular understanding of colorectal cancer and may have implications for the diagnosis, prognosis, and treatment of patients affected by this disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10911911     DOI: 10.1111/j.1749-6632.2000.tb06706.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  24 in total

1.  Don't stop for repairs in a war zone: Darwinian evolution unites genes and environment in cancer development.

Authors:  J Breivik
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

2.  Genetic variation in the promoter of DNMT3B is associated with the risk of colorectal cancer.

Authors:  Qian Bao; Bangshun He; Yuqin Pan; Zhipeng Tang; Ying Zhang; Lili Qu; Yongfei Xu; Chan Zhu; Fuliang Tian; Shukui Wang
Journal:  Int J Colorectal Dis       Date:  2011-04-26       Impact factor: 2.571

3.  Promoter methylation blocks FES protein-tyrosine kinase gene expression in colorectal cancer.

Authors:  Jonathan M Shaffer; Thomas E Smithgall
Journal:  Genes Chromosomes Cancer       Date:  2009-03       Impact factor: 5.006

4.  HLTF gene silencing in human colon cancer.

Authors:  Helen R Moinova; Wei-Dong Chen; Lanlan Shen; Dominic Smiraglia; Joseph Olechnowicz; Lakshmeswari Ravi; Lakshmi Kasturi; Lois Myeroff; Christoph Plass; Ramon Parsons; John Minna; James K V Willson; Sylvan B Green; Jean-Pierre Issa; Sanford D Markowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

5.  CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer.

Authors:  Mark L McCleland; Kathryn Mesh; Edward Lorenzana; Vivek S Chopra; Ehud Segal; Colin Watanabe; Benjamin Haley; Oleg Mayba; Murat Yaylaoglu; Florian Gnad; Ron Firestein
Journal:  J Clin Invest       Date:  2016-01-11       Impact factor: 14.808

Review 6.  Genetic and epigenetic biomarkers in cancer : improving diagnosis, risk assessment, and disease stratification.

Authors:  Mukesh Verma; Daniela Seminara; Fernando J Arena; Christy John; Kumiko Iwamoto; Virginia Hartmuller
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

Review 7.  Genetic and epigenetic marker-based DNA test of stool is a promising approach for colorectal cancer screening.

Authors:  Sung Whan An; Nam Kyu Kim; Hyun Cheol Chung
Journal:  Yonsei Med J       Date:  2009-06-23       Impact factor: 2.759

8.  Lifestyle factors and their combined impact on the risk of colorectal polyps.

Authors:  Zhenming Fu; Martha J Shrubsole; Walter E Smalley; Huiyun Wu; Zhi Chen; Yu Shyr; Reid M Ness; Wei Zheng
Journal:  Am J Epidemiol       Date:  2012-10-18       Impact factor: 4.897

Review 9.  Epigenetics: a molecular link between environmental factors and type 2 diabetes.

Authors:  Charlotte Ling; Leif Groop
Journal:  Diabetes       Date:  2009-12       Impact factor: 9.461

10.  Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing.

Authors:  Katherine E Varley; David G Mutch; Tina B Edmonston; Paul J Goodfellow; Robi D Mitra
Journal:  Nucleic Acids Res       Date:  2009-06-03       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.